Asymmetric Focal Loss Improves Graph Neural Network Prediction of Drug-Drug Interactions

2026-07-08 · Source: Takara TLDR - Daily AI Papers · Field: Technology & Digital — Artificial Intelligence & Machine Learning, Data Science & Analytics, Computational Drug Discovery · Depth: Expert, medium

Summary

A study evaluated whether an asymmetric focal objective, specifically ClinicalFocal loss, could enhance multi-relational drug-drug interaction (DDI) prediction using graph neural networks. Integrating ClinicalFocal loss into a relation-aware graph convolutional network, the model was tested on the TWOSIDES dataset with five-fold cross-validation, comparing it against a binary cross-entropy baseline under identical experimental conditions. Results showed substantial improvements: accuracy increased from 0.699 to 0.892 (+19.3 percentage points), F1 score from 0.700 to 0.894 (+19.4 percentage points), AUROC from 0.766 to 0.914, and AUCPR from 0.714 to 0.860. The false-negative rate decreased from 29.8% to 9.1%, and overall classification error dropped from 30.1% to 10.8%, representing a 64.1% relative reduction. These consistent improvements demonstrate that asymmetric focal optimization significantly boosts DDI prediction performance without architectural changes.

Key takeaway

For machine learning engineers developing drug-drug interaction prediction models, you should consider implementing asymmetric focal loss functions like ClinicalFocal loss. This approach significantly reduces false negatives and improves overall accuracy, achieving a 64.1% relative reduction in classification error without requiring complex architectural changes. Prioritizing difficult positive interactions through loss function design offers a direct, tunable mechanism to enhance model reliability and clinical relevance.

Key insights

Asymmetric focal loss significantly improves graph neural network prediction of drug-drug interactions by emphasizing difficult positive examples.

Principles

• Loss function design directly impacts GNN performance in DDI prediction.
• Prioritizing difficult positive examples enhances classification and ranking.
• Performance gains are achievable without modifying network architecture.

Method

ClinicalFocal loss was integrated into a relation-aware graph convolutional network, utilizing molecular fingerprints, physicochemical descriptors, and learned embeddings, then evaluated on TWOSIDES via five-fold cross-validation.

In practice

• Implement ClinicalFocal loss for DDI prediction tasks.
• Focus on optimizing loss functions for imbalanced datasets.
• Evaluate performance using metrics like F1, AUROC, and AUCPR.

Topics

• Drug-Drug Interactions
• Graph Neural Networks
• Asymmetric Focal Loss
• ClinicalFocal Loss
• Polypharmacy Side Effects
• Machine Learning in Pharma

Code references

• azminewasi/cadgl
• TIML-Group/HODDI
• SZU-ADDG/GenRel-DDI

Best for: AI Engineer, AI Scientist, Machine Learning Engineer, Research Scientist

Related on AIssential

• GraphDiffMed: Knowledge-Constrained Differential Attention with Pharmacological Graph Priors for Medication Recommendation — Combining dual-scale differential attention with pharmacological graph priors significantly enhances medication recommendation safety and quality.
• A Dual Edge Spatial Jacobian Image Graph for Interpretable Diabetic Retinopathy Grading — Interpretable DR grading benefits from graph representations linking spatial lesion-vessel geometry and embedding-biomarker sensitivity.
• A physics-informed graph neural network to approximate docking-based binding affinity for DYRK2 in Alzheimer’s drug repurposing — Integrating physical interaction terms into GNNs can create efficient, interpretable surrogates for computationally intensive molecular docking.
• Critical evaluation of drug response prediction models with DrEval — Current drug response models often yield overly optimistic performance due to evaluation biases and poor generalization.
• A Triple-Modal Contrastive Learning Framework with Sequence, Graph, and 3D Features for Drug-Target Interaction Prediction — TriMod-DTI uses triple-modal contrastive learning with 1D, 2D, and 3D features for superior drug-target interaction prediction.
• OOD-GraphLLM: Graph Large Language Model for Out-of-Distribution Generalized Drug Synergy Prediction — OOD-GraphLLM uses a GraphLLM to predict drug synergy under out-of-distribution conditions by integrating molecular graph and semantic data.

See Counsel's argued verdicts on the open AI decisions leaders are weighing →

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Takara TLDR - Daily AI Papers.